Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing advanced oral antiviral medicines to treat severe viral infections. Its therapeutic pipeline primary centers on developing direct-acting antivirals targeting life-threatening diseases such as hepatitis C, respiratory syncytial virus (RSV), and severe acute respiratory syndromes.